On 2021-09-13 NEU held an investor briefing via Zoom to discuss the imperatives behind the CR to accelerate the Ph2 trials of NNZ-2591.
I'm not sure if a recording of that meeting is available. It was useful to learn that NEU is considering using revenue from Trofinetide to (perhaps) fully fund the Ph3 trials of NNZ-2591. This will enable the majority of the benefits to be retained by NEU investors.
In discussing the possibility with JP subsequent to the meeting, he thought that they had learned enough through the ACAD experience with Trofinetide to be able to undertake the trial and associated FDA work. Given the results of the Ph2 applications, I'm not sure. They may have to recruit/contract specialist resources to assist.
Lets talk ROW, page-25
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |